Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP7 | P09237 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MMP12 | P39900 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9551455 | 1.00 | MME (0.64) | MMELTA4HACEMMP2MMP7 | |
| SCHEMBL9829182 | 1.00 | MME (0.64) | MMELTA4HACEMMP2MMP7 | |
| SCHEMBL8060317 | 0.95 | MME (0.59) | MMELTA4HACEMMP2MMP7 | |
| SCHEMBL8060325 | 0.95 | MME (0.59) | MMELTA4HACEMMP2MMP7 | |
| Glycylleucylphenylalanine SCHEMBL4281374 | 0.95 | ACE (0.62) | MMEACEMMP2MMP7MMP9 | |
| Glycylleucylphenylalanine SCHEMBL4281369 | 0.95 | ACE (0.62) | MMEACEMMP2MMP7MMP9 | |
| SCHEMBL29427560 | 0.94 | MME (0.58) | MMELTA4HACEMMP2MMP7 | |
| SCHEMBL30799577 | 0.94 | MME (0.60) | MMELTA4HMMP2MMP7MMP9 | |
| SCHEMBL2519495 | 0.92 | ACE (0.56) | MMEACEMMP2MMP7MMP9 | |
| SCHEMBL5966413 | 0.92 | OPRM1 (0.65) | MMEOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294802-A1 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | Universität Bielefeld (DE) | 2023-12-27 | — | — | EP | claimed |
| CN-115747058-A | Micro-fluidic chip, detection system and surface treatment reagent combination therein | 上海柏慧康生物科技有限公司 | 2023-03-07 | — | — | CN | claimed |
| WO-2022175222-A1 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | UNIVERSITÄT BIELEFELD (DE) | 2022-08-25 | — | — | WO | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2025136369-A1 | SAFETY-CATCH LINKERS FOR SOLID PHASE PEPTIDE SYNTHESIS | AAPPTec, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250197441-A1 | Safety-Catch Linkers for Solid Phase Peptide Synthesis | AAPPTec, LLC (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2024222960-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | 上海弼领生物技术有限公司 | 2024-10-31 | — | — | WO | disclosed |
| EP-4294802-A1 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | Universität Bielefeld (DE) | 2023-12-27 | — | — | EP | disclosed |
| CN-220176828-U | Microchannel reaction device for synthesizing polypeptide | 厦门胜泽泰医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11793853-B2 | Retinylamine derivitives for treatment of ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| EP-0604552-B1 | METHOD OF SYNTHESIZING DIVERSE COLLECTIONS OF OLIGOMERS | AFFYMAX TECH NV (AN) | 1997-02-12 | — | — | EP | disclosed |
| EP-0754302-A1 | METHODS AND APPARATUS FOR SYNTHESIZING LABELED COMBINATORIAL CHEMICAL LIBRARIES | ONTOGEN CORPORATION (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1996024061-A1 | METHODS AND APPARATUS FOR SYNTHESIZING LABELED COMBINATORIAL CHEMICAL LIBRARIES | ONTOGEN CORPORATION (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| US-4739076-A | WATER SOLUBLE, FOR PEPTIDES AND PROTEINS | SOUTHWICK PHILIP L (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197441-A1 | Safety-Catch Linkers for Solid Phase Peptide Synthesis | PNISR, SPPL2B, VIP | MME 1443/4885LTA4H 3787/4885ACE 1530/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | MME 824/4885LTA4H 3533/4885ACE 1190/4885 |
| US-11793853-B2 | Retinylamine derivitives for treatment of ocular disorders | LRAT, RBP1, RBP4 | MME 1535/4885LTA4H 985/4885ACE 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.